Unlike GLP-1 RAs, dual agonists target both glucose metabolism (via GLP-1) andlipid/energy homeostasis (via Gcg), potentially improving hepatic steatosis,insulin resistance, and metabolic flexibility. The gene discussed is GCG; the disease is fatty liver disease.